Drug Profile

Recombinant staphylokinase - Rhein Minapharm

Alternative Names: Modified SAK; Recombinant staphylokinase variant - Rhein Minapharm Biogenetics; THR-174

Latest Information Update: 28 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ThromboGenics
Developer MiGenTra Egypt; Rhein Minapharm Biogenetics
Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
Mechanism of Action Plasmin stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2025 No recent reports of development identified for preclinical development in Myocardial-infarction in Egypt (IV)
30 Aug 2023 Recombinant staphylokinase is still in preclinical trials for Myocardial infarction in Egypt (MiGenTra Egypt pipeline, August 2023)
30 Aug 2023 Preclinical trials in Pulmonary embolism in Egypt (IV) (MiGenTra Egypt pipeline, August 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com